NO20045552L - Kombinasjonsterapi hvori en serotonin gjenopptaksinhibitor anvendes - Google Patents

Kombinasjonsterapi hvori en serotonin gjenopptaksinhibitor anvendes

Info

Publication number
NO20045552L
NO20045552L NO20045552A NO20045552A NO20045552L NO 20045552 L NO20045552 L NO 20045552L NO 20045552 A NO20045552 A NO 20045552A NO 20045552 A NO20045552 A NO 20045552A NO 20045552 L NO20045552 L NO 20045552L
Authority
NO
Norway
Prior art keywords
disorder
serotonin reuptake
anxiety
reuptake inhibitor
disorders
Prior art date
Application number
NO20045552A
Other languages
English (en)
Norwegian (no)
Inventor
Thomas Ivo Franciscus Cremers
Arne Mork
Sandra Willigers
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of NO20045552L publication Critical patent/NO20045552L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Anesthesiology (AREA)
  • Nutrition Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Finger-Pressure Massage (AREA)
  • Radiation-Therapy Devices (AREA)
  • Thermotherapy And Cooling Therapy Devices (AREA)
NO20045552A 2002-06-20 2004-12-20 Kombinasjonsterapi hvori en serotonin gjenopptaksinhibitor anvendes NO20045552L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39085102P 2002-06-20 2002-06-20
DKPA200200943 2002-06-20
PCT/DK2003/000412 WO2004000326A1 (en) 2002-06-20 2003-06-19 Combination therapy wherein a serotonin reuptake inhibitor is used

Publications (1)

Publication Number Publication Date
NO20045552L true NO20045552L (no) 2004-12-20

Family

ID=30001771

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20045552A NO20045552L (no) 2002-06-20 2004-12-20 Kombinasjonsterapi hvori en serotonin gjenopptaksinhibitor anvendes

Country Status (19)

Country Link
US (1) US20050288355A1 (de)
EP (1) EP1545552B1 (de)
JP (1) JP2005533069A (de)
KR (1) KR20050012284A (de)
CN (1) CN100430063C (de)
AT (1) ATE357920T1 (de)
AU (1) AU2003240434A1 (de)
BR (1) BR0311503A (de)
CA (1) CA2490638C (de)
DE (1) DE60312874T2 (de)
DK (1) DK1545552T3 (de)
ES (1) ES2282632T3 (de)
IL (1) IL165840A0 (de)
MX (1) MXPA04012693A (de)
NO (1) NO20045552L (de)
NZ (1) NZ536624A (de)
PL (1) PL373729A1 (de)
PT (1) PT1545552E (de)
WO (1) WO2004000326A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0413587A (pt) * 2003-08-21 2006-10-17 Lundbeck & Co As H usos de um composto e de um inibidor de glyt-1, composição farmacêutica, kit, e, método para o tratamento de doença
ES2319539T3 (es) * 2003-09-17 2009-05-08 Janssen Pharmaceutica Nv Compuestos heterociclicos condensados como moduladores del receptor de serotonina.
PL1691811T3 (pl) * 2003-12-11 2014-12-31 Sunovion Pharmaceuticals Inc Skojarzenie leku uspokajającego i modulatora neuroprzekaźnikowego oraz sposoby poprawy jakości snu i leczenia depresji
US7598255B2 (en) * 2005-08-04 2009-10-06 Janssen Pharmaceutica Nv Pyrimidine compounds as serotonin receptor modulators
US20090036468A1 (en) * 2007-08-03 2009-02-05 Forest Laboratories Holdings Limited Pharmaceutical compositions containing dopamine receptor ligands and methods of treatment using dopamine receptor ligands
CN107556206A (zh) * 2016-06-30 2018-01-09 陕西合成药业股份有限公司 一种新型5‑羟色胺再摄取抑制剂类化合物及其制备方法和在医学上的应用
CA3059781A1 (en) * 2017-04-10 2018-10-18 Shire Pharmaceuticals Inc. Methods of treatment using an amphetamine prodrug
WO2020014302A1 (en) * 2018-07-11 2020-01-16 Rosenberg Leon I Therapeutic combinations for treatment of cns disorders
US20210393621A1 (en) 2018-10-26 2021-12-23 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
WO2021023805A1 (en) * 2019-08-06 2021-02-11 Initiator Pharma A/S Compound for combination treatment
WO2025018810A1 (ko) * 2023-07-18 2025-01-23 주식회사 지오비스타 동물에 대한 정신질환 또는 행동장애의 예방 또는 치료용 조성물
CN117257815A (zh) * 2023-11-20 2023-12-22 中国人民解放军军事科学院军事医学研究院 Cgp35348在制备抗抑郁药物中的新用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9801538D0 (en) * 1998-01-23 1998-03-25 Merck Sharp & Dohme Pharmaceutical product
US6176242B1 (en) * 1999-04-30 2001-01-23 Medtronic Inc Method of treating manic depression by brain infusion

Also Published As

Publication number Publication date
JP2005533069A (ja) 2005-11-04
MXPA04012693A (es) 2005-03-23
CN100430063C (zh) 2008-11-05
AU2003240434A1 (en) 2004-01-06
IL165840A0 (en) 2006-01-15
DE60312874T2 (de) 2008-01-17
ATE357920T1 (de) 2007-04-15
US20050288355A1 (en) 2005-12-29
CA2490638A1 (en) 2003-12-31
DE60312874D1 (de) 2007-05-10
CA2490638C (en) 2008-01-22
EP1545552A1 (de) 2005-06-29
CN1662246A (zh) 2005-08-31
PT1545552E (pt) 2007-06-15
DK1545552T3 (da) 2007-08-06
NZ536624A (en) 2008-04-30
ES2282632T3 (es) 2007-10-16
BR0311503A (pt) 2005-02-22
KR20050012284A (ko) 2005-01-31
WO2004000326A1 (en) 2003-12-31
EP1545552B1 (de) 2007-03-28
PL373729A1 (en) 2005-09-05

Similar Documents

Publication Publication Date Title
NO20045552L (no) Kombinasjonsterapi hvori en serotonin gjenopptaksinhibitor anvendes
NO20053088L (no) Farmasoytisk preparat inneholdende en beta-3-adrenoseptoragonist og en serotonin og/eller norepinefrin-gjenopptakelsesinhibitor og anvendelse av nevnte preparat for behandling av blaeredysfunksjon.
Law et al. Is the traditional Chinese herb “Artemisia annua” possible to fight against COVID-19?
NO20083204L (no) Kombinasjon av en H3-antagonist/inversagonist og en appetittdemper
NO20070081L (no) Sulfamat og sulfamidderivater for behandling av epilepsi og relaterte sykdommer
TNSN07048A1 (en) Trifluoromethyl substituted benzamides as kinase inhibitors
ATE538650T1 (de) Cannabinoid-rezeptor-antagonisten / inverse agonisten zur behandlung von übergewicht
ATE454372T1 (de) Am histamin-h3-rezeptor wirksame mittel, herstellung und therapeutische anwendungen
MX2009003469A (es) Uso de farmacos que inducen hipotermia para el tratamiento de isquemia.
UA82828C2 (en) The use of enantiomeric pure escitalopram for treatment of depression
CL2011000061A1 (es) Compuestos derivados de tetrahidrocinolinas, inhibidores de la 11-beta-hsd1; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento o profilaxis de la diabetes, obesidad, trastornos de ingestion de comida o dislipidemia.
NO20075920L (no) Assosiasjon mellom ferroquin og et artemisininderivat for behandling av malaria
NO20063267L (no) Kombinasjonen av en serotonin-reopptaksinhibitor og en histamin 3-reseptorantagonist, invers agonist eller partiell agonist
EA200601158A1 (ru) Комбинация ингибитора обратного захвата серотонина и антагониста, обратного агониста или частичного агониста рецептора гистамина 3
NO20061167L (no) Kombinasjonen av en serotonin-reopptaksinhibitor og en glysintransporter type 1-inhibitor for behandling av depresjon
EA200702318A1 (ru) Применение агомелатина для получения лекарственных средств, предназначенных для лечения синдрома смита-магениса
NO20035673L (no) Nye heteroarylderivater, deres fremstilling og anvendelse
NO20082201L (no) Stabile farmasoytiske formuleringer inneholdende escitalopram og bupropion
DE602005011988D1 (de) Histamin-h3-rezeptor inhibitoren, ihre herstellung und therapeutische anwendungen
JP2025510790A5 (de)
CO5680440A2 (es) Terapia de combinacion en donde se utiliza un inhibidor de recaptacion de serotonina
EA200870052A1 (ru) Фармацевтические препаративные формы эсциталопрама модифицированного и пульсирующего высвобождения
Pagliaro et al. Hydroxychloroquine for the treatment of COVID-19: Evidence, possible mode of action and industrial supply of the drug
NO20060229L (no) Gaboxadol for behandling av depresjon og andre affektive lidelser
NO20061425L (no) Kombinasjonen av en serotonin-reopptaksinbibitor og loxapin

Legal Events

Date Code Title Description
CREP Change of representative

Representative=s name: PLOUGMANN & VINGTOFT, POSTBOKS 1003 SENTRUM, 0104